Bharat Biotech's Covaxin human trial start at SRM Hospital, Chennai


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Bharat Biotech's Covaxin human trial start at SRM Hospital, Chennai
Bharat Biotech's Covaxin human trial starts across India

The Phase-1 human clinical trials for Covaxin, a vaccine candidate for Covid-19 developed by Hyderabad-based Bharat Biotech, have begun in Chennai's SRM Medical College Hospital and Research Centre. According to a news report in The News Minute, the first phase of the trials for the vaccine began at SRM hospital on Thursday.

Phase I of the trial will be done on healthy people, aged between 18 and 55 years, having no co-morbid conditions. Women with no pregnancy will also be selected for the trial in the first phase.

During the first phase, the volunteers will be given a controlled dose to see if the vaccine is safe and how much of the dose can be administered.

"Every week, the volunteers who have been administered the vaccine will come for a checkup here. We will test them and review their responses. This will go on for about six months. We will keep sending the results and observations to the Indian Council of Medical Research,” Dr A Sundaram, Dean (Medical Research) of SRM Medical College Hospital and Research told The News Minute.

SRM hospital in Chennai is among the 12 hospitals selected by the Indian Centre for Medical Research for the human trials of Covaxin, Covid-19 vaccine candidate developed by Bharat Biotech in collaboration with ICMR and NIV, Pune.

In phase I, the vaccine would be tested on 375 volunteers. The second phase would include around 750 volunteers from all 12 sites.

In the second phase, 750 people will be recruited and they will be between 12 and 65 years of age.

The process for conducting the clinical trials for Covaxin has also been started at Delhi's All India Insitute of Medical Sciences, Rohtak's Post-Graduate Institute of Medical Sciences and Hyderabad's Nizams Institute of Medical Sciences.

Bharat Biotech has successfully developed COVAXIN, India’s 1st vaccine candidate for COVID-19, in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

The Drug Controller General of India - CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials have already started across India in July 2020.

Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses. 

Bharat Biotech’s track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika. 

Story Credit - www.Indiatoday.in 

Tags : #BharatBiotech #Covaxin #GenomeValley #Hyderabad #ICMR #NIV #SRMHospital #Chennai #LatestCovaxinTrialNews #LatestCovidNewsJuly24

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026